- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07719634
Value of Ultrasound-Guided Microwave Ablation for Breast Fibroadenoma (mua)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Breast fibroadenomas are commonly seen among women worldwide, with the incidence having increased over the past few decades. The breast fibroadenoma arise due to proliferation of ductal or lobular tissue, and their treatment is controversial. Small asymptomatic breast lesions generally do not require treatment, and some surgeons tend to favor conservative management of breast fibroadenoma with regular follow-up, which should be accompanied by auxiliary examination (i.e., ultrasound and/or mammography and pathological assessment) every 3-6 months in order to dynamically monitor the status of breast lesions. However, some patients with large-sized breast fibroadenomas suffering from pain or anxiety are not satisfied with the conservative management approach and seek for treatment. Thus, it is necessary to excise part of the breast fibroadenoma according to therapeutic options that depend on different presenting situations Surgical resection is the most effective treatment option for patients suffering from breast lesions, although it is an invasive procedure. The patients much prefer a better cosmetic outcome and fewer surgically associated complications, which are commonly associated with minimally invasive procedures. Ultrasound-guided percutaneous microwave ablation (MWA) is a new minimally invasive treatment technology used in breast fibroadenoma and has emerged as a hot topic of clinical exploration in recent years. MWA has already shown promising results in treating liver carcinoma and pulmonary tumors, and in the settings of adrenal and renal malignancies Currently, in relation to benign lesions, MWA is considered a promising treatment option for patients with benign thyroid nodules given its advantage of being minimally invasive, scar-free, and relatively safe, and is associated with fewer post-operative complications.
To the best of our knowledge, MWA, as a thermal ablation technique, is increasingly being accepted by surgeons and clearly needs to be evaluated
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion criteria:
- Female participants ≥ 18 years
- Diagnosed with fibroadenoma by clinical and ultrasonographic signs, core needle biopsy done only if atypical fibroadenoma.
- Lesion(s) measurable by ultrasound (e.g., diameter 0.7 - 3.0 cm),distance from breast lesion to the skin and pectoralis muscle exceeding 10 mm and the lesion away from nipple areola area .
- Symptomatic lesion or patient preference for minimally invasive treatment
Exclusion criteria:
- Malignancy or high suspicion of malignancy, BIRADs 4 or more/if pathological proved.
- Active infection.
- Coagulopathy or contraindications to ablation.
- Distance from breast lesion to the skin and pectoralis muscle less than 10 mm and the lesion near nipple areola area .
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: breast fibroadenoma
Fibroadenoma is a common benign breast lesion resulting from the excess proliferation of connective tissue.
Fibroadenomas characteristically contain both stromal and epithelial cells.
Fibroadenomas typically occur in women between the ages of 10 and 40 years.
It is the most common solid breast mass in women of all ages and the most common breast mass in the adolescent and young adult population..
The lesions are well-defined and well-circumscribed clinically, with normal overlying skin.
The lesions are not fixed to the surrounding parenchyma and slide around with palpation, hence the colloquial term a breast "mouse".
|
Patients will be positioned supine or lateri-cumbent, which fully exposed the breast and permitted surgical disinfection.
During the administration of a local anesthetic, the investigators will carefully administer a mixture of 2% lidocaine and 0.9% saline solution into the surrounding breast fibroadenoma to achieve a liquid isolated region to protect the skin, pectoralis, and areola from thermal injury.
Under real-time ultrasound guidance, an MWA antenna will be inserted into the breast fibroadenoma, and therapy will be ceased until the hyper echoic area completely cover the entire breast fibroadenoma
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
assess the efficacy of MWA in reducing fibroadenoma volume
Délai: 12 months
|
Volume Reduction Ratio (VRR): Calculated to see how much the fibroadenoma has shrunk.
Measure 3 orthogonal diameter, calculate volume: L x W x H x0.5 and compare to previous exam.
|
12 months
|
|
To evaluate the safety profile of MWA (adverse events, complications).
Délai: 18 months
|
the investigators will follow up the patients for any appearance of unwanted changes or any complications
|
18 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cosmetic outcome - breast shape and symmetry
Délai: 18 months
|
Assessment of breast shape and symmetry using the Breast Symmetry Scale (1-4), where 1 = excellent symmetry and 4 = marked deformity.
|
18 months
|
|
Cosmetic outcome - scar appearance
Délai: 18 months
|
Assessment of skin scar quality using the Patient and Observer Scar Assessment Scale (POSAS) or Vancouver Scar Scale.
|
18 months
|
|
Cosmetic outcome - skin pigmentation changes
Délai: 18 months
|
Assessment of hyperpigmentation or hypopigmentation at the ablation site compared to the contralateral breast, graded as: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
|
18 months
|
|
Patient satisfaction
Délai: 18 months
|
Assessment of patient satisfaction with the overall procedure and cosmetic results using a 5-point Likert scale.
|
18 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- breast fibroadenoma MWA
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .